Exemplary, BCMA downregulation was identified in approximately 70% of MM patients undergoing BCMA CAR T cell therapy treatment suggesting that specific mutations can result in the loss of BCMA expression on malignant plasma cell clones that are then selected under therapy (5, 230, 231). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.